🇺🇸 FDA

Company profile · Sponsor

Can-Fite

Can-Fite BioPharma

CANF · NYSE biotech RAMAT GAN, L3, USA
Pipeline
20
Drugs
0
Patents
8

Quick answer

Can-Fite (CANF) is a biotech company. headquartered in RAMAT GAN, L3, USA. listed on NYSE. NovaPharmaNews links 20 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker CANF
Exchange NYSE
Company type biotech
Headquarters RAMAT GAN, L3, USA
SEC CIK 0001536196

Pipeline (20)

Search pipeline →

  1. CF101

    Can-Fite

    Keratoconjunctivitis Sicca

    phase 3 small molecule completed

    2 trials

  2. CF101

    Can-Fite

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  3. CF101 1 mg

    Can-Fite

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

  4. CF101 2mg

    Can-Fite

    Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  5. Matching Placebo for Piclidenoson, Piclidenoson

    Can-Fite

    Plaque psoriasis

    phase 3 small molecule active

    1 trial

  6. Namodenoson

    Can-Fite

    Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  7. piclidenoson

    Can-Fite

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  8. CF 102

    Can-Fite

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  9. CF101

    Can-Fite

    Ocular Hypertension

    phase 2 small molecule completed

    1 trial

  10. CF101

    Can-Fite

    Rheumatoid Arthritis

    phase 2 small molecule completed

    3 trials

  11. CF101

    Can-Fite

    Uveitis, Posterior

    phase 2 small molecule terminated

    1 trial

  12. CF101

    Can-Fite

    Osteoarthritis of the Knee

    phase 2 small molecule terminated

    1 trial

  13. CF101 1mg

    Can-Fite

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  14. CF102

    Can-Fite

    Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  15. CF102

    Can-Fite

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    2 trials

  16. Namodenoson

    Can-Fite

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule active

    1 trial

  17. Namodenoson 25mg

    Can-Fite

    Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  18. Namodenoson, Matching placebo for namodenoson

    Can-Fite

    Non-Alcoholic Steatohepatitis (NASH) with F1-3 fibrosis

    phase 2 small molecule active

    1 trial

  19. Piclidenoson

    Can-Fite

    COVID-19

    phase 2 small molecule completed

    1 trial

  20. Piclidenoson

    Can-Fite

    Lowe Syndrome

    phase 2 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12213990

    A3 adenosine receptor ligand for use for achieving a fat loss effect

    Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11291681

    Method for treating fibrotic liver tissue using Cl-IB-MECA

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10780106

    Method for treating NASH accompanied by fibrosis using Cl-IB-MECA

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10265337

    Use of A3 adenosine receptor agonist in osteoarthritis treatment

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9549943

    A3 adenosine receptor ligands for use in treatment of a sexual dysfunction

    Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9387220

    Method for inducing hepatocyte proliferation and uses thereof

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9102698

    Process for the synthesis of IB-MECA

    Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8987228

    Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis

    Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Can-Fite?

Can-Fite (CANF) is a biotech company. headquartered in RAMAT GAN, L3, USA. listed on NYSE. NovaPharmaNews links 20 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Can-Fite sponsor?

We track 20 ClinicalTrials.gov-linked programs for Can-Fite, including CF101 and 19 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Can-Fite company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.